Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Justin M. Schmidt"'
Autor:
Arti Phatak, Keri DePatis, Denise M. Kolanczyk, Tran H. Tran, Justin M. Schmidt, Kathleen Vest, Milena Murray, Mary Ann Kliethermes
Publikováno v:
Currents in pharmacy teachinglearning. 12(11)
The objective of this study was to identify perceived barriers and factors influencing student pursuit of research during pharmacy school.A voluntary, paper-based or electronic questionnaire was administered to all pharmacy students at a private coll
Autor:
Justin M. Schmidt
Publikováno v:
Oral Anticoagulation Therapy ISBN: 9783319546414
Unfractionated heparin is the preferred anticoagulant while the effects of thrombolysis are evident. Oral anticoagulants are not recommended to be administered concurrently with thrombolytics and while direct oral anticoagulants have not been adequat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff12c1a98500533a86cdb1145ca1e81c
https://doi.org/10.1007/978-3-319-54643-8_23
https://doi.org/10.1007/978-3-319-54643-8_23
Autor:
Justin M. Schmidt, Christie Schumacher, Brian T. Cryder, Ana C. Quiñones-Boex, Sally A. Arif, Nicole G. Rockey
Publikováno v:
Currents in Pharmacy Teaching and Learning. 6:716-722
The objective of this article is to describe the impact of a pharmacy practice department scholarship committee on faculty scholarship attitudes and abilities, as well as change in faculty perception since initial evaluation. A questionnaire was dist
Publikováno v:
Currents in Pharmacy Teaching and Learning. 2:68-71
Background A Writing Club was established to provide internal peer review before external submission of written documents, such as manuscripts and abstracts. The Writing Club initially met face-to-face once a month for two hours to review submitted d
Autor:
Carrie A. Sincak, Justin M. Schmidt
Publikováno v:
Annals of Pharmacotherapy. 43:1107-1114
Objective To review the pharmacology, microbiology, in vitro susceptibility, pharmacokinetics, clinical trial data, safety, and tolerability of iclaprim, a novel dihydrofolate reductase (DHFR) inhibitor. Data Sources A MEDLINE search was conducted fr